A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy

Casey B Williams1 Avera Cancer Institute, Sioux Falls, SD, USA

Caitlin McMahon2 Foundation Medicine, Inc., Cambridge, MA, USA

Siraj M Ali2 Foundation Medicine, Inc., Cambridge, MA, USA

Mark Abramovitz1 Avera Cancer Institute, Sioux Falls, SD, USA

Kirstin A Williams1 Avera Cancer Institute, Sioux Falls, SD, USA

Jessica Klein1 Avera Cancer Institute, Sioux Falls, SD, USA

Heidi McKean1 Avera Cancer Institute, Sioux Falls, SD, USA

Roman Yelensky2 Foundation Medicine, Inc., Cambridge, MA, USA

Thomas J George Jr3 University of Florida College of Medicine, Gainesville, FL, USA

Julia A Elvin2 Foundation Medicine, Inc., Cambridge, MA, USA

Salil Soman4 Beth Israel Deaconess Medical Center, Boston, MA, USA

Doron Lipson2 Foundation Medicine, Inc., Cambridge, MA, USA

Juliann Chmielecki2 Foundation Medicine, Inc., Cambridge, MA, USA

Deborah Morosini2 Foundation Medicine, Inc., Cambridge, MA, USA

Vincent A Miller2 Foundation Medicine, Inc., Cambridge, MA, USA

Philip J Stephens2 Foundation Medicine, Inc., Cambridge, MA, USA

Jeffrey S Ross2 Foundation Medicine, Inc., Cambridge, MA, USA;5 Albany Medical College, Albany, NY, USA

Brian Leyland-Jones1 Avera Cancer Institute, Sioux Falls, SD, USACorrespondence[email protected]

References